戻る
ZYUS Life Sciences Corporation (ZLSCF)価格
ZLSCF 株価推移チャート
ZLSCF 収入
ZYUS Life Sciences Corporation
$0.05
-91.05%
$-0.5
終値： Feb 10, 16:00:00 GMT-5
$0.05
0%
$0
アフターマーケット：Feb 10, 20:00:00 GMT-5
最新の利益結果: Q4 '24
報告済み: 2025-04-30
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
ZLSCFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
ZYUS Life Sciences Corporation ZLSCFの前四半期の収益はどうでしたか？
ZYUS Life Sciences Corporationの収益見積もりはいくらですか？
ZYUS Life Sciences Corporationの収益品質スコアはどれくらいですか？
ZYUS Life Sciences Corporationはいつ収益を報告しますか？
ZYUS Life Sciences Corporationの予想収益はいくらですか？
ZYUS Life Sciences Corporationは収益予想を上回りましたか？
主要データ
前終値
$0.56
始値
$0.0401
当日レンジ
$0.0401 - $0.0501
52週レンジ
$0.0401 - $0.66
取引高
--
平均取引高
649
1株当たり利益(TTM)
-0.33
配当利回り
--
時価総額
$4.0M
ZYUS LIFE SCIENCES CORPとは何ですか？
ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.